Literature DB >> 21069870

A differential association of Apolipoprotein E isoforms with the amyloid-β oligomer in solution.

Jitka Petrlova1, Hyun-Seok Hong, Daniel A Bricarello, Ghimire Harishchandra, Gary A Lorigan, Lee-Way Jin, John C Voss.   

Abstract

The molecular pathogenesis of disorders arising from protein misfolding and aggregation is difficult to elucidate, involving a complex ensemble of intermediates, whose toxicity depends upon their state of progression along distinct processing pathways. To address the complex misfolding and aggregation that initiates the toxic cascade resulting in Alzheimer's disease (AD), we have developed a 2,2,6,6-tetramethylpiperidine-1-oxyl-4-amino-4-carboxylic acid spin-labeled amyloid-β (Aβ) peptide to observe its isoform-dependent interaction with the apoE protein. Although most individuals carry the E3 isoform of apoE, ∼15% of humans carry the E4 isoform, which is recognized as the most significant genetic determinant for Alzheimer's. ApoE is consistently associated with the amyloid plaque marker for AD. A vital question centers on the influence of the two predominant isoforms, E3 and E4, on Aβ peptide processing and hence Aβ toxicity. We used electron paramagnetic resonance (EPR) spectroscopy of incorporated spin labels to investigate the interaction of apoE with the toxic oligomeric species of Aβ in solution. EPR spectra of the spin-labeled side chain report on side chain and backbone dynamics as well as the spatial proximity of spins in an assembly. Our results indicate oligomer binding involves the C-terminal domain of apoE, with apoE3 reporting a much greater response through this conformational marker. Coupled with SPR binding measurements, apoE3 displays a higher affinity and capacity for the toxic Aβ oligomer. These findings support the hypothesis that apoE polymorphism and Alzheimer's risk can largely be attributed to the reduced ability of apoE4 to function as a clearance vehicle for the toxic form of Aβ.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21069870      PMCID: PMC3016465          DOI: 10.1002/prot.22891

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  53 in total

1.  C-terminal interactions of apolipoprotein E4 respond to the postprandial state.

Authors:  Sarada D Tetali; Madhu S Budamagunta; John C Voss; John C Rutledge
Journal:  J Lipid Res       Date:  2006-04-21       Impact factor: 5.922

2.  Electron paramagnetic resonance spectroscopy of site-directed spin labels reveals the structural heterogeneity in the N-terminal domain of apoA-I in solution.

Authors:  Jens O Lagerstedt; Madhu S Budamagunta; Michael N Oda; John C Voss
Journal:  J Biol Chem       Date:  2007-01-04       Impact factor: 5.157

3.  Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils.

Authors:  Danny M Hatters; Ning Zhong; Earl Rutenber; Karl H Weisgraber
Journal:  J Mol Biol       Date:  2006-08-07       Impact factor: 5.469

Review 4.  Apolipoprotein E structure: insights into function.

Authors:  Danny M Hatters; Clare A Peters-Libeu; Karl H Weisgraber
Journal:  Trends Biochem Sci       Date:  2006-07-03       Impact factor: 13.807

5.  Experimental constraints on quaternary structure in Alzheimer's beta-amyloid fibrils.

Authors:  Aneta T Petkova; Wai-Ming Yau; Robert Tycko
Journal:  Biochemistry       Date:  2006-01-17       Impact factor: 3.162

6.  Combining the rapid MTT formazan exocytosis assay and the MC65 protection assay led to the discovery of carbazole analogs as small molecule inhibitors of Abeta oligomer-induced cytotoxicity.

Authors:  Hyun-Seok Hong; Izumi Maezawa; Nianhuan Yao; Bailing Xu; Ruben Diaz-Avalos; Sandeep Rana; Duy H Hua; R Holland Cheng; Kit S Lam; Lee-Way Jin
Journal:  Brain Res       Date:  2006-12-08       Impact factor: 3.252

7.  Dynamics of Asp23-Lys28 salt-bridge formation in Abeta10-35 monomers.

Authors:  Bogdan Tarus; John E Straub; D Thirumalai
Journal:  J Am Chem Soc       Date:  2006-12-20       Impact factor: 15.419

8.  The structure of the Alzheimer amyloid beta 10-35 peptide probed through replica-exchange molecular dynamics simulations in explicit solvent.

Authors:  Andrij Baumketner; Joan-Emma Shea
Journal:  J Mol Biol       Date:  2006-11-10       Impact factor: 5.469

9.  Lipid-induced extension of apolipoprotein E helix 4 correlates with low density lipoprotein receptor binding ability.

Authors:  Vinita Gupta; Vasanthy Narayanaswami; Madhu S Budamagunta; Taichi Yamamato; John C Voss; Robert O Ryan
Journal:  J Biol Chem       Date:  2006-11-01       Impact factor: 5.157

10.  Candidate anti-A beta fluorene compounds selected from analogs of amyloid imaging agents.

Authors:  Hyun-Seok Hong; Izumi Maezawa; Madhu Budamagunta; Sandeep Rana; Aibin Shi; Robert Vassar; Ruiwu Liu; Kit S Lam; R Holland Cheng; Duy H Hua; John C Voss; Lee-Way Jin
Journal:  Neurobiol Aging       Date:  2008-11-20       Impact factor: 4.673

View more
  24 in total

1.  Protective spin-labeled fluorenes maintain amyloid beta peptide in small oligomers and limit transitions in secondary structure.

Authors:  Robin Altman; Sonny Ly; Silvia Hilt; Jitka Petrlova; Izumi Maezawa; Tamás Kálai; Kálmán Hideg; Lee-Way Jin; Ted A Laurence; John C Voss
Journal:  Biochim Biophys Acta       Date:  2015-09-14

Review 2.  Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer's disease.

Authors:  Evan Dorey; Nina Chang; Qing Yan Liu; Ze Yang; Wandong Zhang
Journal:  Neurosci Bull       Date:  2014-03-20       Impact factor: 5.203

3.  Binding of apolipoprotein E inhibits the oligomer growth of amyloid-β peptide in solution as determined by fluorescence cross-correlation spectroscopy.

Authors:  Sonny Ly; Robin Altman; Jitka Petrlova; Yu Lin; Silvia Hilt; Thomas Huser; Ted A Laurence; John C Voss
Journal:  J Biol Chem       Date:  2013-02-21       Impact factor: 5.157

4.  ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions.

Authors:  Philip B Verghese; Joseph M Castellano; Kanchan Garai; Yinong Wang; Hong Jiang; Aarti Shah; Guojun Bu; Carl Frieden; David M Holtzman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-25       Impact factor: 11.205

5.  Cerebrospinal Fluid Proteins as Regulators of Beta-amyloid Aggregation and Toxicity.

Authors:  Kayla M Pate; Regina M Murphy
Journal:  Isr J Chem       Date:  2017-01-18       Impact factor: 3.333

6.  Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.

Authors:  Leon M Tai; Tina Bilousova; Lisa Jungbauer; Stephen K Roeske; Katherine L Youmans; Chunjiang Yu; Wayne W Poon; Lindsey B Cornwell; Carol A Miller; Harry V Vinters; Linda J Van Eldik; David W Fardo; Steve Estus; Guojun Bu; Karen Hoppens Gylys; Mary Jo Ladu
Journal:  J Biol Chem       Date:  2013-01-04       Impact factor: 5.157

7.  Aggregation of thrombin-derived C-terminal fragments as a previously undisclosed host defense mechanism.

Authors:  Jitka Petrlova; Finja C Hansen; Mariena J A van der Plas; Roland G Huber; Matthias Mörgelin; Martin Malmsten; Peter J Bond; Artur Schmidtchen
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-04       Impact factor: 11.205

Review 8.  ApoE and Aβ in Alzheimer's disease: accidental encounters or partners?

Authors:  Takahisa Kanekiyo; Huaxi Xu; Guojun Bu
Journal:  Neuron       Date:  2014-02-19       Impact factor: 17.173

9.  Mapping the interactions between the Alzheimer's Aβ-peptide and human serum albumin beyond domain resolution.

Authors:  Moustafa Algamal; Julijana Milojevic; Naeimeh Jafari; William Zhang; Giuseppe Melacini
Journal:  Biophys J       Date:  2013-10-01       Impact factor: 4.033

10.  APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease.

Authors:  Katherine L Youmans; Leon M Tai; Evelyn Nwabuisi-Heath; Lisa Jungbauer; Takahisa Kanekiyo; Ming Gan; Jungsu Kim; William A Eimer; Steve Estus; G William Rebeck; Edwin J Weeber; Guojun Bu; Chunjiang Yu; Mary Jo Ladu
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.